You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Claims for Patent: 4,158,055

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,158,055

Title:	Administration of 16.alpha.,17.alpha.-cyclopentylidenedioxy-9.alpha.-fluor O-11.beta.,21-dihydroxy-1,4-pregnadiene-3,20-dione 21-acetate
Abstract:	A method of treating topical inflammation in mammals by the administration of 16.alpha.,17.alpha.-cyclopentylidenedioxy-9.alpha.-fluoro-11.beta.,21-dihy droxy-1,4-pregnadiene-3,20-dione 21-acetate in a pharmaceutically acceptable carrier.
Inventor(s):	Shultz; Walter (Spring Valley, NY), Sieger; George M. (Montvale, NJ), Krieger; Charles (Clifton, NJ)
Assignee:	American Cyanamid Company (Stamford, CT)
Application Number:	05/754,917
Patent Claims:	1. A method of ameliorating inflammation in a mammal which comprises administering topically to said mammal an anti-inflammatory effective amount of 16.alpha.,17.alpha.-cyclopentylidenedioxy-9.alpha.-fluoro-11.beta.,21-dihy droxy-1,4-pregnadiene-3,20-dione 21-acetate in association with a topical pharmaceutically acceptable carrier. 2. A method in accordance with claim 1, wherein the anti-inflammatory agent is incorporated in a topical cream. 3. A method in accordance with claim 1, wherein the anti-inflammatory agent is incorporated in a topical ointment. 4. A method in accordance with claim 1, wherein the anti-inflammatory agent is incorporated in a topical foam. 5. A method in accordance with claim 1, wherein the anti-inflammatory agent is incorporated in an ophthalmic ointment. 6. A method in accordance with claim 1, wherein the anti-inflammatory agent is incorporated in a topical lotion. 7. A method of treating inflammation in a mammal comprising administering topically to said mammal an anti-inflammatory effective amount of the steroid, 16.alpha.,17.alpha.-cyclopentylidenedioxy-9.alpha.-fluoro-11.beta.,21-dihy droxy-1,4-pregnadiene-3,20-dione 21-acetate in association with a topical pharmaceutically acceptable carrier in which the steroid is present in a concentration range of from about 0.01% to about 0.50%.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.